

PROACTIVE NATIONWIDE IBD PATIENT MONITORING AND MANAGEMENT USING PROMS - IMPLEMENTATION AND INITIAL RESULTS

Aviva Ben Baruch

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A pilot study implementing an IBD patient-reported outcome measures platform at Maccabi Healthcare Services achieved 17.6% participation, with responders showing significantly higher rates of disease monitoring tests compared to non-responders despite similar disease activity.

KEY POINTS

- The platform sent validated IBD questionnaires every 3 months via text message to 777 IBD registry patients, with results integrated into the electronic medical record and triggering digital alerts to an IBD nurse for red flags or low scores.
- Overall participation was 137 out of 777 patients (17.6%), with 23% of responders showing red flags and 38% having sub-threshold IBD-control scores.
- Responders were significantly older (mean 48.8 vs 39.9 years, $p<0.001$) and had higher BMI (25.3 vs 24.1 kg/m², $p=0.026$) than non-responders, but did not differ in disease type, medication use including biologics, or hospitalization rates.
- Significantly more disease monitoring tests were performed among responders, including calprotectin (27.0% vs 17.8%, $p=0.014$) and CRP (38.0% vs 29.1%, $p=0.040$) in the 3 months following initial response.
- The study was supported by a quality improvement grant from Takeda pharmaceutical and the authors recommend increasing response rates through education and training.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/1f89a584-743c-11ee-a716-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.